|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Pregnancy cat.||B1 (AU) B (US)|
|Legal status||℞-only (US)|
|Metabolism||Hepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)|
|Half-life||Approximately 40 hours|
|Excretion||Renal, 80% (of which 49% unchanged); fecal (5 to 8%)|
|Mol. mass||296.407 g/mol|
| (what is this?)
Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there is tentative data that it may be better than granisetron.
Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy, or as a single oral capsule one hour before chemotherapy. The oral formulation was approved on August 22, 2008 for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV.
- Billio, A; Morello, E; Clarke, MJ (2010 Jan 20). "Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.". The Cochrane database of systematic reviews (1): CD006272. PMID 20091591.
- De Leon A (2006). "Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting". Proceedings (Baylor University. Medical Center) 19 (4): 413–6. PMC 1618755. PMID 17106506.
- Waknine, Yael (September 4, 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. Retrieved 2008-09-04. Freely available with registration.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|